일회 Donepezil 투약이 알쯔하이머병 환자에 미치는 영향 및 반응군 예측 인자로서의 가능성

참고문헌 (37)

1. Whitehouse PJ, "Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain", Science, 215, pp.1237~1239 (1982)
2. Whitehouse PJ, "Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis", Ann Neurol, 10, pp.122~126 (1981)
3. Giacobini E, "Pharmacotherapy of Alzheimer disease: new drugs and novel strategies", Prog Brain Res, 98, pp.447~454 (1993)
4. Davis RE, "Cholinergic therapies for Alzheimer’s disease", Arzneimittelforschung Drug Res, 45, pp.425~431 (1995)
5. Rogers SL, "Donepezil Improves Cognition and Global Function in Alzheimer Disease: A 15-Week, Double-blind, Placebo-Controlled Study", Arch Int Med, 158, pp.1021~1031 (1998)
6. Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease", Neurology, 50, pp.136~145 (1998)
7. Cummings JL, "Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations", Am J Geriatr Psychiatry, 11, pp.131~145 (2003)
8. Schneider LS, "Delay in nursing home placement with donepezil", J Am Geriatr Soc, 52, pp.1024~1026 (2004)
9. Kwak YT, "Changes of Quantitative EEG after Donepezil Treatment in Alzheimer’s Disease", J Korean Neurol Assoc, 19, pp.245~250 (2001)
10. Giacobini E, "Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer’s disease", Alzheimer Dis Assoc Disord, 14, pp.3~10 (2000)
11. Wilcock GK, "The treatment of Alzheimer’s disease with anticholinesterase drugs", Alzheimer Rev, 4, pp.73~77 (1993)
12. Byrne EJ, "Tetrahydroaminoacridine and Alzheimer’s disease", BMJ, 308, pp.368~369 (1994)
13. Winkler MA, "Tacrine for Alzheimer’s disease- Which patient, what dose", JAMA, 271, pp.1023~1024 (1994)
14. Schneider LS, "Do blood pressure and age predict response to tacrine(THA) in Alzheimer’s disease? A preliminary report", Psychopharmacol Bull, 27, pp.309~314 (1991)
15. Kanetaka H, "Prediction of response to donepezil in Alzheimer’s disease: combined MRI analysis of the substantia innominata and SPECT measurement of cerebral perfusion", Nucl Med Commun, 29, pp.568~573 (2008)
16. Hanyu H, "Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer’s disease", Dement Geriatr Cogn Disord, 15, pp.177~182 (2003)
17. Riekkinen Jr P, "Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer’s disease", Neuroreport, 8, pp.1845~1849 (1997)
18. Sahakian BJ, "Further analysis of the cognitive effects of tetrahydroaminoacridine(THA) in Alzheimer’s disease: assessment of attentional and mnemonic function using CANTAB", Psychopharmacology, 110, pp.395~401 (1993)
19. Alhainen K, "Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco- EEG in patients with Alzheimer’s disease", Neurosci Lett, 127, pp.113~116 (1991)
20. Pietrzak RH, "Methodological improvements in quantifying cognitive change in clinical trials: an example with single-dose administration of donepezil", J Nutr Health Aging, 13, pp.268~273 (2009)
21. McKhann G, "Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under Auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
22. Kang Y, "A validity study on the Korean Mini-Mental State Examination(K-MMSE) in dementia patients", J Korean Neurol Assoc, 15, pp.300~308 (1997)
23. Hughes CP, "A new clinical scale for the staging of dementia", Br J Psychiatry, 140, pp.566~572 (1982)
24. Kang Y, "Samsung Neuropsychological Screening Battery. In: Current research in dementia", The Korean Dementia Association, pp.99~107 (1998)
25. Bendat JS, "Random Data Analysis and Measurement Procedures. 2nd ed", pp.121~132 (1986), Wiley Interscience Press
26. Jann MW, "Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors", Clin Pharmacokinet, 41, pp.719~739 (2002)
27. 곽용태, "알쯔하이머병과 소혈관성 치매에서 Donepezil 복용 후 K-MMSE의 변화와 의미 있는 K-MMSE 변화를 보이는 알쯔하이머병 환자의 특징", 생물정신의학, 12(2), pp.17~28 (2005), 대한생물정신의학회
28. Doraiswamy PM, "The Alzheimer’s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s disease", Alzheimer Dis Assoc Disord, 15, pp.174~183 (2001)
29. Farlow M, "A controlled trial of tacrine in Alzheimer’s disease", JAMA, 268, pp.2523~2529 (1992)
30. Jahanshahi M, "A preliminary investigation of the running digit span as a test of working memory", Behav Neurol, 20, pp.17~25 (2008)
31. Callaway E, "Cholinergic activity and constraints on information processing", Biol Psychol, 33, pp.1~22 (1992)
32. Sunderland T, "Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations", Brain Res, 472, pp.371~389 (1988)
33. Snyder PJ, "Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor", Alzheimers Dement, 1, pp.126~135 (2005)
34. Almkvist O, "Responder characteristics to a single oral dose of cholinesterase inhibitor: a doubleblind placebo-controlled study with tacrine in Alzheimer patients", Dement Geriatr Cogn Disord, 12, pp.22~32 (2001)
35. McLendon BM, "Defining meaningful change in Alzheimer’s disease trials: the donepezil experience", J Geriatr Psychiatry Neurol, 12, pp.39~48 (1999)
36. Eagger SA, "Serum levels of tacrine in relation to clinical response in Alzheimer’s disease", Int J Geriatr Psychiatry, 7, pp.115~119 (1992)
37. Pomara N, "Pretreatment postural blood pressure drop as possible predictor of response to the cholinesterase inhibitor Velnacrine(HP 029) in Alzheimer’s disease", Psychopharmacol Bull, 27, pp.301~307 (1991)

관련 논문AI추천